

Simultaneous determination of benzocaine and cetylpyridinium chloride in tablets by first-derivative spectrophotometric method

L.R. Paschoal *, W.A. Ferreira

Instituto de Farmácia e Nutrição-Universidade de Alfenas-UNIFENAS Rod. MG 179 Km 0, Campus Universitário, 37130-000 Alfenas MG, Brazil

Received 17 May 2000; accepted 5 September 2000


Abstract

A new spectrophotometric method for the simultaneous determination of benzocaine and cetylpyridinium chloride in pharmaceutical tablets, which does not require any preliminary separation or treatment of the samples, is described. The quantitative determination of both drugs was carried out using the first derivative values measured at 231.40 and 310.00 nm for benzocaine and at 220.70 nm for cetylpyridinium chloride using the zero-crossing method. The calibration graphs were linear in the ranges from 10 to 25 mg/l of benzocaine and from 4 to 20 mg/l of cetylpyridinium chloride. The developed method was successfully applied for the assay of pharmaceutical tablets and proved to be simple, sensitive and selective. Thermogravimetric techniques, Karl Fischer and loss on drying were also used for a stoichiometric evaluation of the substances studied. © 2000 Elsevier Science S.A. All rights reserved.


Keywords: Benzocaine; Cetylpyridinium chloride; Derivative spectrophotometry; Thermogravimetry; Pharmaceutical tablets.

1. Introduction

Pharyngitis, tonsillitis, colds and mouth and throat infections are illnesses regularly treated using antiseptic and analgesic medicines [1]. Cetylpyridinium chloride (I), an antiseptic quaternary ammonium, and benzocaine (II), used as a local anesthetic, are found associated in tablets [1,2].



I C₂₁H₃₈ClN.H₂O



II C₉H₁₁NO₂

Several methods have been used for qualitative and quantitative determination of cetylpyridinium chloride

and benzocaine. They include thermogravimetry [3], volumetry [4–6] and spectrophotometry [3–6]. On the contrary of derivative spectrophotometric methods [8–17], these methods do not permit simultaneous analysis of both compounds without previous procedures of separation and extraction.

Thus, this paper describes the first derivative spectrophotometric method for the simultaneous analysis of benzocaine and cetylpyridinium chloride in tablets, without previous procedures of separation. Other techniques such as thermogravimetry, Karl Fischer and loss on drying [7] were also used for qualitative and quantitative evaluation of the raw materials used.

2. Experimental

2.1. Apparatus

The zero-order spectra and the respective derivatives were obtained on a spectrophotometer Shimadzu model

* Corresponding author. Fax: + 55-35-32993226.

E-mail addresses: lr_paschoal@yahoo.com (L.R. Paschoal), weverferreira@yahoo.com (W.A. Ferreira).

UV-1601 PC double beam, with a slit width of 2 nm. The first derivative of the spectrum curves of the references and samples were recorded in a 1 cm quartz cells over the range of 200–350 nm ($\Delta\lambda = 1.0$ nm). The scan speed was of 8.3 nm/s (middle).

The TG–DTG curves were obtained using a Mettler TA 4000 thermoanalyzer system, with a heating rate of 20°C/min ranging from 25 to 900°C, a synthetic air in flow rate of 20 ml/min and an alumina crucible. The sample mass ranged from 6.0 to 9.0 mg.

The loss on drying was determined using an OHAUS model MB 200 dryer with infrared heating, temperature registration and a balance with a programming device. The sample mass was in the range of 10.00 ± 0.5 g.

The Karl Fischer equipment used to determine the water content in the samples was a Mettler model DL 18 Titrator employing a Merck reagent that corresponds to the following relationship: 1 ml = 5 mg H₂O.




Fig. 1. (a) Zero-order absorption spectra of cetylpyridinium chloride (16 mg/l); and (b) benzocaine (15 mg/l), obtained in 1:1 water–alcohol (v/v) solution.




Fig. 2. First derivative absorption spectra of: (a) cetylpyridinium chloride; and (b) benzocaine obtained in 1:1 water–alcohol (v/v) solution.

2.2. Chemicals and pharmaceutical preparation

The cetylpyridinium chloride and the benzocaine pharmaceutical raw materials were acquired from the distributors Henrifarma and Synth, respectively (Brazil).

The used tablets were a well-known commercial product, Cetil Drops (Luper). The contents of the tablets were:

- Cetylpyridinium chloride 2.5 mg
- Benzocaine 2.0 mg

The alcohol used was absolute ethanol, an analytical reagent Merck (Germany) with a purity of 99.8%.

2.2.1. Standard solutions

2.2.1.1. Stock solutions. Benzocaine (10 mg) and cetylpyridinium chloride were separately dissolved in 1:1 water–alcohol (v/v). These solutions were used for the preparation of calibration curves and for spectra after appropriate dilution with the same solvent.

2.2.1.2. Working standard solutions. Using standard stock solutions, serial solutions were prepared containing 10–25 mg/l of benzocaine and 4–20 mg/l of cetylpyridinium chloride for derivative spectrophotometry measurements.

2.2.1.3. Mixed standard working solution. Using standard solutions, we prepared solutions of benzocaine at 12 mg/l while varying the concentrations of cetylpyridinium chloride (4, 8, 12, 15 and 20 mg/l). We also made solutions of cetylpyridinium chloride at 15 mg/l while varying the concentrations of benzocaine (10, 15, 20, 25 and 30 mg/l).

2.3. Procedure

2.3.1. Zero-order UV spectra

The zero-order spectra (Fig. 1) of the compounds were separately obtained in a 1:1 water–alcohol (v/v) solution containing cetylpyridinium chloride (16 mg/l) and benzocaine (15 mg/l).

2.3.2. First-derivative UV spectra

The first derivative spectra (Fig. 2) of the compounds was obtained separately starting from the zero order spectra of cetylpyridinium chloride (16 mg/l) and benzocaine (15 mg/l). Using the zero-crossing method, three points were observed for the cetylpyridinium chloride analyzes (209.60, 220.70 and 240.50 nm) and four points for the benzocaine analyzes (214.00, 231.40, 258.80 and 310.00 nm). These results suggest the possible absorption wavelengths that we could use to selectively dose these materials.




Fig. 3. The TG–DTG plot of cetylpyridinium chloride.




Fig. 4. The TG–DTG plot of the benzocaine.

2.3.3. Calibration graphs

The benzocaine calibration curves were made by plotting the derivative amplitude, 1D , at 214.00, 231.40, 258.80 and 310.00 nm against the concentration (10, 15, 20 and 25 mg/l). The calibration curves of cetylpyridinium chloride were made by plotting the derivative amplitude, 1D , at 209.60, 220.70 and 240.50 nm against the concentration (4, 8, 12, 16 and 20 mg/l).

2.3.4. Analysis of tablets

Tablets were accurately weighed and cut into small pieces in a mortar. A mass equivalent to one tablet was dissolved in 50 ml of the 1:1 water–alcohol (v/v) solution. This solution was filtered and 15 ml was diluted again in 50 ml 1:1 water–alcohol (v/v) to obtain the cetylpyridinium chloride (15 mg/l) and benzocaine (12 mg/l) solutions.

2.3.5. Tablets simulation

Tablet simulations were prepared in 1:1 water–alcohol (v/v) solutions with cetylpyridinium chloride and benzocaine, in agreement with the item 2.2.1.2. to obtain a cetylpyridinium chloride (15 mg/l) and benzocaine (12 mg/l) solution.

3. Results and discussion

3.1. Thermogravimetric (TG–DTG) experiments

The TG–DTG curves of the cetylpyridinium chloride (Fig. 3) show mass loss in two stages between 25 and 275°C. The first step is between 25 and 100°C, due to the loss of 5.1% as a result of the evaporation of 1.02 molecules of water. The second step is between 157 and 275°C, due to the loss of 93.57% for the burning of organic matter. The TG–DTG curves of the benzocaine (Fig. 4) shows mass loss in one step, between 86.5 and 277.5°C presenting loss mass of 99.36% of organic matter.

3.2. Karl Fischer

On the basis of the molecular structures of the products **I** and **II**, only cetylpyridinium chloride presents a molecule of water corresponding to 5% of its composition. However 6.5 and 0.15% of water in cetylpyridinium chloride and benzocaine, respectively, were found by the Karl Fischer technique.

3.3. Loss on drying

When cetylpyridinium chloride was submitted to a temperature of 110°C/30 min, a loss of 3.7% by evaporation of 0.73 molecules of water was observed. When submitted to a temperature of 140°C/30 min, a loss of 4.3% by evaporation of 0.85 molecules of water was observed. And when submitted to a temperature of 150°C/30 min, a loss of 4.7% by evaporation of 0.93 molecules of water was observed.

The results obtained by drying, Karl Fisher and thermogravimetric analysis were compared (Table 1) and showed small variations in the value of water depending on the technique used.

3.4. Derivative spectrophotometry

Direct UV absorption measurements (zero order spectra) were found to be inapplicable to the analyzes of benzocaine and cetylpyridinium chloride in binary mixture because of spectra interferences (Fig. 1). However the first-derivative spectra permitted the simultaneous determination of both compounds (Fig. 2).

Linear relationships between derivative amplitude and drug concentration were obtained over the concentration range 10–25 mg/l for benzocaine and 4–20 mg/l for cetylpyridinium chloride. Linear regressions were obtained at 209.60, 220.70 and 240.50 nm for cetylpyridinium chloride and at 214.00, 231.40, 258.80 and 310.00 nm for benzocaine. The best results for the tablets and your respective ‘simulation’ (Table 2) were obtained with linear regressions at 220.70 nm for

Table 1

Comparison of the amount of water found in cetylpyridinium chloride when analyzed by thermogravimetric analysis, loss on drying and Karl Fischer

Loss on drying			Thermogravimetric analysis			Karl Fischer	
Temperature (°C) (30/min)	%	H ₂ O molecules	Temperature (°C)	%	H ₂ O molecules	%	H ₂ O molecules
110	3.7	0.73	25–100	5.1	1.02	6.5	1.29
140	4.3	0.85					
150	4.7	0.93					

cetylpyridinium chloride (Fig. 5) and at 310.00 nm (Fig. 7) for benzocaine (see also Fig. 6).

The possible interference of excipients and associated drugs in commercial pharmaceutical formulations was investigated. Thus, by the comparison of the results obtained between the simulation and the tablets, it has been found that the excipients do not interfere with the determination of benzocaine and cetylpyridinium chloride by the presently proposed method.

The mean percentage RSD and percentage recovery could be considered to be very satisfactory, at least for the level of the examined concentrations of benzocaine and cetylpyridinium chloride.

The study of the concentration influence of one component on the other was performed by varying the concentrations of one and maintaining the other fixed (Tables 3 and 4).

The percentage RSD and percentage recovery values (Table 3) showed that at 231.4 and 310 nm, the proposed method has adequate sensibility and accuracy for benzocaine evaluation whereas, at 220.7 nm, the proposed method has adequate sensibility and accuracy for cetylpyridinium chloride evaluation.

The study of the disintegration–dissolution profile of the tablets containing cetylpyridinium chloride and benzocaine is in progress using this first derivative spectrophotometric method. The results of that research will be published shortly.

4. Conclusions

The proposed methodology based on first order derivative UV spectrophotometry, permitted identification and quantification of the combined benzocaine and cetylpyridinium chloride, in tablet preparations. Quantitative determination may be done at 231.5 and 310.00 nm for benzocaine and at 220.70 nm for cetylpyridinium chloride.

The method employs low cost reagents and requires a short time for analyzes. Reproducibility, accuracy and

sensitivity of this method are satisfactory. The method may be considered suitable for routine analysis of large number of samples.




Fig. 5. Calibration graph of cetylpyridinium chloride obtained at 220.7 nm. The found linear regression was: $A = -1.33 \times 10^{-4} + 1.22 \times 10^{-3} \cdot c$ (mg/l), with $r = 0.9999$.




Fig. 6. Calibration graph of benzocaine obtained at 231.5 nm. The found linear regression was: $A = 3.51 \times 10^{-5} + 3.37 \times 10^{-3} \cdot c$ (mg/l), with $r = 0.9999$.

Table 2
Values found for benzocaine and cetylpyridinium chloride in binary mixture (simulation) and tablets

Drug	Simulation ^a				Tablets ^a			
	Theoretical value (mg)	Total amount found (mg)	Recovered (%)	RSD (%)	Theoretical value (mg)	Total Amount found (mg)	Recovered (%)	RSD (%)
Benzocaine ¹ D _{231.40 nm}	2.00	1.95	97.50	0.44	2.00	2.20	110.00	0.24
Benzocaine ¹ D _{310.00 nm}	2.00	1.93	96.50	0.28	2.00	2.00	100.01	0.52
Cetylpyridinium chloride ¹ D _{220.70 nm}	2.50	2.56	102.40	1.15	2.50	2.42	96.80	1.31

^a The values are the averages of four determinations.

Table 3
Values found for benzocaine and for cetylpyridinium chloride when the concentration of cetylpyridinium chloride was varied in the presence of benzocaine (12 mg/l)

Pharmaceutical raw material (mg/l)	Benzocaine (nm)				Cetylpyridinium chloride (nm)									
	Total amount found (mg/l)				Recovered (%)				Total amount found (mg/l)			Recovered(%)		
Theoretical value (mg/l)	214.0 ^a	231.4 ^b	258.8 ^c	310.0 ^d	214.0	231.4	258.8	310.0	209.6	220.7	240.5	209.6	220.7	240.5
Benzocaine/12 Cetylpyridinium chloride/4	11.61	12.24	11.84	12.13	96.75	102.00	98.67	101.08	<4	4.95	4.68		123.75	117.00
Benzocaine/12 Cetylpyridinium chloride/8	11.56	12.13	11.40	12.05	96.33	101.08	96.00	100.42	>12	9.45	9.55		118.12	119.38
Benzocaine/12 Cetylpyridinium chloride/12	11.84	12.42	11.63	12.31	98.67	103.50	96.92	102.58	12.44	13.06	11.98	103.67	108.83	99.83
Benzocaine/12 Cetylpyridinium chloride/15	11.65	12.40	11.70	12.13	97.08	103.33	97.50	101.08	<11	15.44	13.87	-	102.93	92.47
Benzocaine/12 Cetylpyridinium chloride/20	11.65	12.66	12.14	12.31	97.08	105.50	101.16	102.58	<10	19.70	17.93	-	98.50	89.65

^a RSD = 0.91%.

^b RSD = 1.63%.

^c RSD = 2.33%.

^d RSD = 0.97%.

Table 4

Values found for cetylpyridinium chloride and for benzocaine when the concentration of benzocaine was varied in the presence of cetylpyridinium chloride (15 mg/l)

Pharmaceutical raw material (mg/l)	Benzocaine (nm)								Cetylpyridinium chloride/nm					
	Total amount found (mg/l)				Recovered (%)				Total amount found (mg/l)			Recovered (%)		
Theoretical value (mg/l)	214.0	231.4	258.8	310.0	214.0	231.4	258.8	310.0	209.6	220.7 ^a	240.5 ^b	209.6	220.7	240.5
Cetylpyridinium chloride/15 benzocaine/10	9.66	10.28	9.64	10.22	96.60	102.80	96.40	102.20	<4	16.11	14.40		107.40	96.00
Cetylpyridinium chloride/15 benzocaine/15	14.23	15.39	14.44	15.66	94.87	102.60	96.27	104.40	>20	16.90	16.57		112.67	110.47
Cetylpyridinium chloride/15 benzocaine/20	19.57	20.46	19.58	20.44	97.85	102.30	97.90	102.20	>20	16.80	17.38		112.00	115.87
Cetylpyridinium chloride/15 benzocaine/25	24.50	25.45	24.75	25.78	98.00	101.80	99.00	103.12	>20	16.40	16.57		109.33	110.47
Cetylpyridinium chloride/15 benzocaine/30	29.20	31.00	30.05	30.92	97.33	103.33	100.17	103.07	>20	16.70	16.03		111.33	106.87

^a RSD = 1.95%.

^b RSD = 6.86%.




Fig. 7. Calibration graph of benzocaine obtained at 310.0 nm. The found linear regression was: $A = 2.16 \times 10^{-5} + 4.96 \times 10^{-3} \cdot c$ (mg/l), with $r = 0.9999$.

Acknowledgements

We would like to thank the FAPEMIG Foundation (Brazil), for the financial support (CDS-396/97 and 70396/97).

References

- [1] A. Korolkovas, Dicionário Terapêutico Guanabara, Rio de Janeiro, 1996, pp. 4.1 and 18.4.
- [2] The Merck Index, 11th ed., Rahway, 1989, p. 311 and 594.
- [3] L.R. Paschoal, M.R. Costa, Dosagem de cloreto de *n*-cetilpiridinium como matéria prima para especialidades farmacêuticas, XI Encontro Regional da Sociedade Brasileira de Química, Lavras-MG (Brazil), 1997, p. 45. Cloreto de Cetilpiridinio, Brazilian Pharmacopoeia, 1999 (in prelo).
- [4] US Pharmacopoeia XXIII and the National Formulary XVIII,

- US Pharmacopoeial Convention, Rockville, MD, 1995, pp. 173 and 329.
- [5] European Pharmacopoeia, third ed., Strasbourg, 1997, pp. 455 and 586.
- [6] Brazilian Pharmacopoeia, third ed., Organização Andrei Editora S.A, São Paulo, Brazil, 1997, p.144.
- [7] Nogueira Prista, A. Correia Alves, R.M.R. Morgado, Técnica Farmacêutica e Farmácia Galênica, vol. I, fourth Ed., Porto, 1992, pp 866–885.
- [8] M. Karali, S. Ozkirimli, A. Gursoy, Simultaneous determination of medazepam and hyoscine butylbromide in tablets by second-derivative ultraviolet spectrometry, *Farmaco* 53 (1998) 62–64.
- [9] M. Moore, V. Sithipitaks, Photolytic degradation of frusemide, *J. Pharm. Pharmacol.* 35 (1983) 489–493.
- [10] M. Dinc, F. Onur, Application of a new spectrophotometric method for the analysis of a ternary mixture containing metamizol, paracetamol and caffeine in tablets, *Anal. Chim. Acta* 359 (1998) 93–106.
- [11] M. Bonazzi, R. Gotti, V. Andrisano, V. Cavrini, Derivative UV determination of atenolol and metoprolol in single and multi-component pharmaceutical dosage forms, *Farmaco* 51 (1996) 733–738.
- [12] N. Erk, F. Onur, Simultaneous determination of analgine and paracetamol in tablet by spectrophotometric methods, *Anal. Lett.* 30 (1997) 1201–1210.
- [13] C.V.N. Prasad, C. Parihar, K. Sunil, P. Parimoo, Simultaneous determination of amiloride HCl, hydrochlorothiazide and atenolol in combined formulations by derivative spectroscopy, *J. Pharm. Biomed. Anal.* 17 (1998) 877–884.
- [14] A.F.M. El Walily, A. El Gindy, M.F. Bedair, Application of first-derivative UV spectrophotometry, TLC-densitometry and liquid chromatography for the simultaneous determination of mebeverine hydrochloride and sulphiride, *J. Pharm. Biom. Anal.* 21 (1999) 535–548.
- [15] D. Ozer, H. Senel, Determination of lisinopril from pharmaceutical preparations by derivative UV spectrophotometry, *J. Pharm. Biom. Anal.* 21 (1999) 691–695.
- [16] S. Gangwal, P. Trivedi, Spectrophotometric methods for simultaneous determination of sulphadoxine and pyrimethamine in two component tablet formulations, *Asian J. Chem.* 11 (1999) 917–921.
- [17] H.Y. Aboul-Enein, M. Surmeian, Analysis of salbutamol and related impurities by derivative spectrometry, *Arch. Pharm. Pharm. Med. Chem.* 333 (2000) 75–78.